<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="r-tp-pcnsl-zhao">
    <meta name="study:title" content="PB3233 - High-dose Thiotepa combined with Rituximab and Pomalidomide is a perfect alternative chemotherapy regimen for relapsed/refractory primary central nervous system diffuse large B cell lymphoma">
    <meta name="study:fileName" content="Abstracts/R-TP-PCNS-DLBCL-ZHAO-PB3233.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="2L+">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="Thiotepa,Rituximab,Monoclonal Antibody,Pomalidomide,Immunomodulatory drugs,Chemotherapy,CIT,High-dose Methotrexate">

    <title>PB3233: R-TP Regimen in R/R PCNS-DLBCL (Zhao) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css"> </head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PB3233 - R-TP (Rituximab, Thiotepa, Pomalidomide) in R/R PCNS-DLBCL</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996 2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848-.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=16)</h4>
                    <p>R/R PCNS-DLBCL Pts post 1L chemo. Aim: Evaluate response rate & tolerance of R-TP regimen.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (R-TP Regimen)</h4>
                    <p>Rituximab (375mg/m²), Thiotepa (60mg/m²) D1; Pomalidomide 4mg PO D1-14. Q21D for up to 6 cycles.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M3.75 3A.75.75 0 003 3.75v16.5a.75.75 0 00.75.75h16.5a.75.75 0 00.75-.75V3.75a.75.75 0 00-.75-.75H3.75zm14.25 1.5H6v13.5h12V4.5zm-10.5 3a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5H9a.75.75 0 000-1.5H6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (mF/U 8mo)</h4>
                    <p>Post 2 cycles (N=16): ORR <span class="highlight-value">100%</span> (CR 0%). Post 6 cycles (N=11): ORR <span class="highlight-value">100%</span>, CRR <span class="highlight-value">72.7%</span>.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>Generally mild hematologic toxicity. R-TP shows high efficacy & good tolerability; promising for R/R PCNS-DLBCL.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PB3233 - High-dose Thiotepa combined with Rituximab and Pomalidomide is a perfect alternative chemotherapy regimen for relapsed/refractory primary central nervous system diffuse large B cell lymphoma</h1>
            <p class="abstract-sub-header">Xia Zhao, Zhihe Liu</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PB3233 | Publication Only</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Primary Central Nervous System Diffuse Large B-cell Lymphoma (PCNS-DLBCL) is rare, aggressive, with poor prognosis.</li>
                        <li>First-line treatment: Multi-drug chemotherapy + high-dose methotrexate (MTX).</li>
                        <li>Over 50% of patients experience relapse or refractory (R/R) disease.</li>
                        <li>No established standard of care for R/R PCNS-DLBCL after first-line chemotherapy.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To evaluate the treatment response rate and tolerance of the R-TP regimen (Rituximab, Thiotepa, Pomalidomide) in patients with R/R PCNS-DLBCL after first-line chemotherapy.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Study Type: Single-center study (China).</li>
                        <li>Patient Population: R/R PCNS-DLBCL patients treated between Jan 2023 - Dec 2024.</li>
                        <li>R-TP Regimen (21-day cycles, up to 6 cycles for Pomalidomide):
                            <ul class="list-circle list-inside ml-4">
                                <li>Rituximab: 375 mg/m² (Day 1 of each cycle).</li>
                                <li>Thiotepa: 60 mg/m² (Day 1 of each cycle).</li>
                                <li>Pomalidomide: 4 mg PO daily (Days 1-14 of each of the first six cycles).</li>
                            </ul>
                        </li>
                        <li>Data Collected: Baseline data, overall response rates, adverse events.</li>
                        <li>Data Cutoff: February 2025.</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">R-TP Regimen for R/R PCNS-DLBCL</h3>
                        <div class="schema-enrollment">
                            <strong>R/R PCNS-DLBCL Pts (N=16 Enrolled)</strong>
                            <span>Post 1st Line Chemotherapy</span>
                            <span>(Single Center, China, Jan 2023 - Dec 2024)</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 100%; background-color: var(--sobi-light-blue-bg); border-color: var(--sobi-dark-blue);">
                                <strong>R-TP Regimen (Q21D)</strong>
                                <span>Rituximab 375mg/m² D1</span>
                                <span>Thiotepa 60mg/m² D1</span>
                                <span>Pomalidomide 4mg PO D1-14 (first 6 cycles)</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-assessment-points">
                           <span>Treatment Response Rate (ORR, CRR)</span>
                           <span>Tolerance / Adverse Events</span>
                        </div>
                    </div>
                </div>
            </div> <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=16)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Median Age: 66 years (range, 49-74).</li>
                        <li>Gender Ratio (Male:Female): 5:3.</li>
                        <li>IELSG Risk Score:
                            <ul class="list-circle list-inside ml-4">
                                <li>Low-risk: 18.8%</li>
                                <li>Intermediate-risk: 81.2%</li>
                            </ul>
                        </li>
                        <li>Baseline Hematology: WBC, Hemoglobin, Platelets mostly normal at enrollment.</li>
                        <li>Hans Algorithm Subtype: Non-GCB 87.5%.</li>
                    </ul>
                </div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (Median Follow-up: 8 months)</h2>
                    <p class="text-sm mb-1">All patients received at least 2 cycles of R-TP.</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li><strong>After 2 Cycles (N=16):</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>Overall Response Rate (ORR): 100%.</li>
                                <li>Complete Response (CR) Rate: 0%.</li>
                            </ul>
                        </li>
                        <li><strong>After 6 Cycles (N=11 completed):</strong>
                             <ul class="list-circle list-inside ml-4">
                                <li>Overall Response Rate (ORR): 100%.</li>
                                <li>Complete Response (CR) Rate: 72.7%.</li>
                            </ul>
                        </li>
                    </ul>
                    <div class="chart-container my-4">
                        <svg id="rtpResponseChart" width="400" height="300"></svg>
                        <div id="rtpResponseLegend" class="legend"></div>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary</h2>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Common adverse events were generally mild hematologic toxicity.</li>
                        </ul>
                </div>
            </div> </div> <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>The R-TP regimen (Rituximab, Thiotepa, Pomalidomide) demonstrated high efficacy in patients with R/R PCNS-DLBCL, with a 100% ORR after 2 cycles and a 72.7% CRR in patients completing 6 cycles.</li>
                <li>The treatment showed good tolerability, with common adverse events being generally mild hematologic toxicity.</li>
                <li>R-TP offers a promising treatment option for this challenging patient population.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>AE, Adverse Event; CR, Complete Remission; CRR, Complete Response Rate; D, Day; DLBCL, Diffuse Large B-Cell Lymphoma; ECOG, Eastern Cooperative Oncology Group; GCB, Germinal Center B-cell like; IELSG, International Extranodal Lymphoma Study Group; LOT, Lines of Therapy; mg/m², Milligrams per square meter; MTX, Methotrexate; ORR, Overall Response Rate; PCNS-DLBCL, Primary Central Nervous System Diffuse Large B-Cell Lymphoma; PO, Per Os (by mouth); Pom, Pomalidomide; Q21D, Every 21 Days; R, Rituximab; R/R, Relapsed or Refractory; R-TP, Rituximab, Thiotepa, Pomalidomide; WBC, White Blood Cell Count.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Zhao X, Liu Z. High-dose Thiotepa combined with Rituximab and Pomalidomide is a perfect alternative chemotherapy regimen for relapsed/refractory primary central nervous system diffuse large B cell lymphoma. Abstract #PB3233 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PB3233 | Abstract Release: 05/14/25 | Presentation: 06/12/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div> <script defer src="abstract_features.js"></script>
    <script>
    function drawRtpResponseChart(containerId, legendContainerId) {
        const chartTitle = "Response to R-TP Regimen";
        // Data: Post 2 cycles (N=16): ORR 100% (CR 0%). Post 6 cycles (N=11): ORR 100%, CRR 72.7%.
        // For simplicity, we'll show the 6-cycle data for CRR, and ORR (which is 100% for both timepoints).
        // It's a bit tricky to show both timepoints for CRR in one simple bar chart without making it complex.
        // We will focus on the 6-cycle data for the chart, and mention 2-cycle ORR in text.
        const chartData = [
            { response: "ORR (Post 6c, N=11)", rate: 100, color: "var(--sobi-teal-darker)" },
            { response: "CR (Post 6c, N=11)", rate: 72.7, color: "var(--sobi-teal)" }
            // PR for 6 cycles would be 100 - 72.7 = 27.3%
        ];
        const orrPost2Cycles = 100;


        const svg = d3.select(containerId);
        const legendContainer = d3.select(legendContainerId);
        svg.selectAll("*").remove();
        legendContainer.selectAll("*").remove();

        let containerWidth = 400;
        const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
        if (chartWrapper) {
            containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.90, 300);
        }
        
        const svgWidth = containerWidth;
        const svgHeight = +svg.attr("height");
        const margin = { top: 60, right: 20, bottom: 70, left: 50 }; // Increased bottom for labels
        const chartWidth = svgWidth - margin.left - margin.right;
        const chartHeight = svgHeight - margin.top - margin.bottom;

        if (chartWidth <= 0 || chartHeight <=0) return;

        const g = svg.append("g").attr("transform", `translate(${margin.left},${margin.top})`);

        const xScale = d3.scaleBand()
            .domain(chartData.map(d => d.response))
            .range([0, chartWidth])
            .padding(0.4); // Adjusted padding

        const yScale = d3.scaleLinear().domain([0, 100]).range([chartHeight, 0]);

        g.append("g").attr("transform", `translate(0,${chartHeight})`).call(d3.axisBottom(xScale))
            .selectAll("text").attr("class", "axis-text").style("font-size", "9px")
            .call(wrapAxisText, xScale.bandwidth());


        g.append("g").call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d + "%"))
            .selectAll("text").attr("class", "axis-text").style("font-size", "10px");
        
        g.append("text").attr("transform", "rotate(-90)").attr("y", 0 - margin.left + 10).attr("x", 0 - (chartHeight / 2))
            .attr("dy", "1em").style("text-anchor", "middle").attr("class", "axis-label").text("Response Rate (%)");

        g.append("g").attr("class", "grid")
            .call(d3.axisLeft(yScale).ticks(5).tickSize(-chartWidth).tickFormat(""))
            .selectAll("line").style("stroke", "var(--sobi-light-gray)").style("stroke-opacity", "0.7");

        g.selectAll(".bar").data(chartData).enter().append("rect")
            .attr("class", "bar").attr("x", d => xScale(d.response)).attr("y", d => yScale(d.rate))
            .attr("width", xScale.bandwidth()).attr("height", d => chartHeight - yScale(d.rate))
            .attr("fill", d => d.color).attr("rx", 3).attr("ry", 3);

        g.selectAll(".bar-label").data(chartData).enter().append("text")
            .attr("class", "chart-label").attr("x", d => xScale(d.response) + xScale.bandwidth() / 2)
            .attr("y", d => yScale(d.rate) - 5).attr("text-anchor", "middle")
            .style("font-size", "10px").style("fill", "var(--sobi-dark-text)")
            .text(d => `${d.rate.toFixed(1)}%`);
        
        svg.append("text").attr("x", svgWidth / 2).attr("y", margin.top / 2 - 5)
            .attr("text-anchor", "middle").style("font-size", "13px").style("font-weight", "600")
            .style("fill", "var(--sobi-dark-blue)").text(chartTitle);
        
        svg.append("text").attr("x", svgWidth / 2).attr("y", margin.top / 2 + 15)
            .attr("text-anchor", "middle").style("font-size", "10px").style("font-style", "italic")
            .style("fill", "var(--sobi-dark-text)")
            .text(`ORR post 2 cycles (N=16): ${orrPost2Cycles}% (CR 0%)`);


        const legendItems = legendContainer.selectAll(".legend-item").data(chartData).enter().append("div").attr("class", "legend-item");
        legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
        legendItems.append("span").text(d => d.response.replace(" (Post 6c, N=11)", "")); // Cleaner legend label
    }

    // Helper function to wrap axis text
    function wrapAxisText(text, width) {
      text.each(function() {
        var text = d3.select(this),
            words = text.text().split(/\s+/).reverse(),
            word,
            line = [],
            lineNumber = 0,
            lineHeight = 1.1, // ems
            y = text.attr("y"),
            dy = parseFloat(text.attr("dy") || 0),
            tspan = text.text(null).append("tspan").attr("x", 0).attr("y", y).attr("dy", dy + "em");
        while (word = words.pop()) {
          line.push(word);
          tspan.text(line.join(" "));
          if (tspan.node().getComputedTextLength() > width && line.length > 1) {
            line.pop();
            tspan.text(line.join(" "));
            line = [word];
            tspan = text.append("tspan").attr("x", 0).attr("y", y).attr("dy", ++lineNumber * lineHeight + dy + "em").text(word);
          }
        }
      });
    }
    
    function debounce(func, wait) {
        let timeout;
        return function executedFunction(...args) {
            const later = () => { clearTimeout(timeout); func(...args); };
            clearTimeout(timeout);
            timeout = setTimeout(later, wait);
        };
    };

    const debouncedDrawRtpChart = debounce(() => drawRtpResponseChart("#rtpResponseChart", "#rtpResponseLegend"), 250);
    
    window.addEventListener('resize', debouncedDrawRtpChart);
    document.addEventListener('DOMContentLoaded', debouncedDrawRtpChart);
    if (document.readyState === "complete" || document.readyState === "interactive") {
         setTimeout(debouncedDrawRtpChart, 0); 
    }
    </script>
</body>
</html>
